This company is no longer actively trading as an independent public company (delisted, acquired, or ceased operations). This profile is retained for reference.
Awakn Life Sciences is a biotechnology company with clinical operations; researching, developing, and delivering psychedelic medicine to better treat Addiction. Awakn’s team consists of world leading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies, and enabling technologies to treat Addiction.
Awakn will also deliver evidence backed psychedelic therapies for Addiction in clinics in the UK and Europe and through licensing partnerships globally.
Stock Performance
Awakn Life Sciences News 57 articles
- Awakn Life Sciences Provides Update on R&D Programs, Progressing Novel Therapeutics for Alcohol Use Disorder and PTSD
- Awakn Announces Positive Outcome of Pre-IND Meeting with FDA for AWKN-002 in Alcohol Use Disorder
- Awakn Life Sciences Announces Credit Facility
- Awakn Life Sciences Enters into Binding Letter of Intent for Acquisition of Awakn by Graft Polymer (UK) Plc
- Awakn Announces Promising Results from Aminoindane New Chemical Entity Pre-Clinical Program
- Awakn Announces Opening of Four Additional AWKN-001 Phase 3 Trial Sites
- Awakn Partners with the University of Nottingham for in Vivo Testing of Aminoindane New Chemical Entity (NCE) Pre-Clinical Program
- Awakn Selects Eurofins Discovery for Pharmacology Testing in New Chemical Entity (NCE) Pre-Clinical Program
- Awakn Life Sciences Announces Upsizing and Closing of Tranche of Private Placement Financing
- Awakn Announces Key Progress in Its Aminoindane Pre-Clinical Program
- Awakn Announces First Patient Screened in Phase 3 Clinical Trial of AWKN-001 for Severe Alcohol Use Disorder
- Awakn Life Sciences Announces Closing of Tranche of Private Placement and Warrant Extension
- Awakn Life Sciences Provides Update on Aminoindane New Chemical Entity Patent Portfolio
- Awakn Life Sciences Announces Closing of Tranche of Private Placement
- Awakn Life Sciences Discusses Filing of Financial Statements
- Awakn Life Sciences Announces Closing of Tranche of Private Placement
- Awakn Life Sciences Announces Launch of Licensing Partnership Agreement with Oklahoma Based Clinic
- Awakn Life Sciences Announces Conditional Approval of CSE Listing
- Awakn Life Sciences Completes Successful Investigative Study to Establish Dissociative Effect of a Proprietary Sublingual S-Ketamine Oral Thin Film Formulation in Harmful Drinkers
- Awakn Life Sciences Submits Clinical Trial Application for Phase III Trial Of AWKN-P001
- PharmAla Biotech named Exclusive MDMA Supply Partner to Awakn Life Sciences
- Awakn Life Sciences’ Phase III Trial to Be Delivered in the UK National Health Service
- Awakn Life Sciences Receives Regulatory Approval for Flagship Clinic in London to Begin Delivering Treatments
- Awakn Life Sciences Signs Its Third Licensing Partnership Agreement in North America, and First in New York
- Awakn Life Sciences Signs Its Third Licensing Partnership Agreement in North America, and First in New York
- Awakn Life Sciences Secures Funding to Expand Nordic Commercial Operations
- Awakn Life Sciences Reports Strong Q2 2022 Results
- Awakn Life Sciences Signs Drug Development Agreement with Catalent for Zydis(R) Technology to Conduct Feasibility Studies to Improve Differentiation of Its MDMA Program
- Awakn Life Sciences Signs Agreement with a Leading Drug Development Company to Deepen IP Moat for Its Lead Program
- Awakn Life Sciences Signs Second Licensing Partnership Agreement and Expands Commercial Operations Into Canada
- Awakn Life Sciences Expands Commercial Operations into the U.S. – First Licensing Partnership Agreement with Revitalist
- Awakn Life Sciences Receives Regulatory Approval for Flagship Clinic in London to Begin Delivering Treatments
- Awakn Life Sciences Provides a Business and Corporate Update
- PRO: A Closer Look at Awakn Life Sciences + Cybin and Mindmed Updates (VIDEO)
- Awakn Life Sciences Initiates Follow-On Behavioral Study to Focus on Gambling Disorder
- Anthony Tennyson, CEO of Awakn Life Sciences Sits in the Investor Hotseat: Stream #1
- Awakn Life Sciences Provides Shareholder Update on Three Operational Ketamine-Assisted Therapy Clinics in the UK and Norway
- Awakn Life Sciences Announces Closing of Private Placement
- Awakn Life Sciences Receives Regulatory to Begin Delivering Treatments in London Clinic
- Awakn Life Sciences Drug Discovery Program Files Patent Application for a New Class of Entactogen-Like Molecules
Showing the 40 most recent of 57 articles.